Lipid abnormalities and cardiovascular risk in the elderly

References

• Shepherd J. Issues surrounding age: vascular disease in the elderly. Curr Opin Lipidol 2001;12:601–9
   PubMed Web of Science ®Google Scholar
• Kalantzi KJ, Milionis HJ, Mikhailidis DP, Goudevenos JA. Lipid lowering therapy in the elderly: is there a benefit? Curr Pharm Des 2006;12:3945–60
   PubMed Web of Science ®Google Scholar
• Williams MA, Fleg JL, Ades PA, et al. Secondary prevention of coronary heart disease in the elderly (with emphasis on patients > or = 75 years of age): an American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation 2002;105:1735–43
   PubMed Web of Science ®Google Scholar
• Aronow WS, Ahn C. Risk factors for new coronary events in a large cohort of very elderly patients with and without coronary artery disease. Am J Cardiol 1996;77:864–6
   PubMed Web of Science ®Google Scholar
• Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med 1971;74:1–12
   PubMed Web of Science ®Google Scholar
• Kronmal RA, Cain KC, Ye Z, Omenn GS. Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data. Arch Intern Med 1993;153:1065–73
   PubMed Web of Science ®Google Scholar
• Kreisberg RA, Kasim S. Cholesterol metabolism and aging. Am J Med 1987;82:54–60
   PubMed Web of Science ®Google Scholar
• Ericsson S, Eriksson M, Vitols S, et al. Influence of age on the metabolism of plasma low density lipoproteins in healthy males. J Clin Invest 1991;87:591–6
   PubMed Web of Science ®Google Scholar
• Krumholz HM, Seeman TE, Merrill SS, et al. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA 1994;272:1335–40
   PubMed Web of Science ®Google Scholar
• Forette B, Tortrat D, Wolmark Y. Cholesterol as risk factor for mortality in elderly women. Lancet 1989;1:868–70
   Google Scholar
• Casiglia E, Mazza A, Tikhonoff V, et al. Total cholesterol and mortality in the elderly. J Intern Med 2003;254:353–62
   PubMed Web of Science ®Google Scholar
• Pekkanen J, Nissinen A, Vartiainen E, et al. Changes in serum cholesterol level and mortality: a 30-year follow-up. The Finnish cohorts of the seven countries study. Am J Epidemiol 1994;139:155–65
   PubMed Web of Science ®Google Scholar
• Weverling-Rijnsburger AW, Blauw GJ, Lagaay AM, et al. Total cholesterol and risk of mortality in the oldest old. Lancet 1997;350:1119–23
   Google Scholar
• Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623–30
   PubMed Web of Science ®Google Scholar
• Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358:2026–33
   PubMed Web of Science ®Google Scholar
• Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007;115:450–8
   PubMed Web of Science ®Google Scholar
• Austin MA, Rodriguez BL, McKnight B, et al. Low-density lipoprotein particle size, triglycerides, and high-density lipoprotein cholesterol as risk factors for coronary heart disease in older Japanese-American men. Am J Cardiol 2000;86:412–16
   PubMed Web of Science ®Google Scholar
• Aronow WS, Herzig AH, Etienne F, et al. 41-month follow-up of risk factors correlated with new coronary events in 708 elderly patients. J Am Geriatr Soc 1989;37:501–6
   PubMed Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study. Curr Med Res Opin 2004;20:1691–701
   PubMed Web of Science ®Google Scholar
• Milionis HJ, Rizos E, Goudevenos J, et al. Components of the metabolic syndrome and risk for first-ever acute ischemic nonembolic stroke in elderly subjects. Stroke 2005;36:1372–6
   PubMed Web of Science ®Google Scholar
• Lozano JV, Pallarésb V, Cea-Calvoc L, et al. Serum lipid profiles and their relationship to cardiovascular disease in the elderly. The PREV-ICTUS Study. Curr Med Res Opin 2008; 24:659–70
   PubMed Web of Science ®Google Scholar
• Davidson MH, Kurlandsky SB, Kleinpell RM, Maki KC. Lipid management and the elderly. Prev Cardiol 2003;6:128–33; quiz 34–5
   Google Scholar
• Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227–39
   PubMed Web of Science ®Google Scholar
• Milionis HJ, Rizos E, Mikhailidis DP. Smoking diminishes the beneficial effect of statins: observations from the landmark trials. Angiology 2001;52:575–87
   Google Scholar
• Daskalopoulou SS, Daskalopoulos ME, Mikhailidis DP, Liapis CD. Lipid management and peripheral arterial disease. Curr Drug Targets 2007;8:561–70
   PubMed Web of Science ®Google Scholar
• Paraskevas KI, Athyros VG, Briana DD, et al. Statins exert multiple beneficial effects on patients undergoing percutaneous revascularization procedures. Curr Drug Targets 2007;8:942–51
   PubMed Web of Science ®Google Scholar
• Youssef F, Gupta P, Mikhailidis DP, Hamilton G. Risk modification in patients with peripheral arterial disease: a retrospective survey. Angiology 2005;56:279–87
   PubMed Web of Science ®Google Scholar
• Afilalo J, Duque G, Steele R, et al. Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. J Am Coll Cardiol 2008;51:37–45
   PubMed Web of Science ®Google Scholar
• Rosenson RS. Current overview of statin-induced myopathy. Am J Med 2004;116:408–16
   PubMed Web of Science ®Google Scholar
• Sica DA, Gehr TW. Rhabdomyolysis and statin therapy: relevance to the elderly. Am J Geriatr Cardiol 2002;11:48–55
   PubMedGoogle Scholar
• Lipka L, Sager P, Strony J, et al. Efficacy and safety of coadministration of ezetimibe and statins in elderly patients with primary hypercholesterolaemia. Drugs Aging 2004;21:1025–32
   PubMed Web of Science ®Google Scholar
• Paraskevas KI, Liapis CD, Hamilton G, Mikhailidis DP. Can statins reduce perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery? Eur J Vasc Endovasc Surg 2006;32:286–93
   PubMed Web of Science ®Google Scholar
• Bronheim D. Statins and the perioperative period. Semin Cardiothorac Vasc Anesth 2007;11:231–6
   PubMedGoogle Scholar
• Welten GM, Chonchol M, Hoeks SE, et al. Statin therapy is associated with improved outcomes in vascular surgery patients with renal impairment. Am Heart J 2007;154:954–61
   PubMed Web of Science ®Google Scholar
• Kaplan RC, Heckbert SR, Furberg CD, Psaty BM. Predictors of subsequent coronary events, stroke, and death among survivors of first hospitalized myocardial infarction. J Clin Epidemiol 2002;55:654–64
   PubMed Web of Science ®Google Scholar
• Kasiske BL, O'Donnell MP, Cleary MP, Keane WF. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int 1988;33:667–72
   PubMed Web of Science ®Google Scholar
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7–22
   PubMed Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004;57:728–34
   Google Scholar
• Shepherd J, Kastelein JJ, Bittner V, et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol 2007;2:1131–9
   PubMed Web of Science ®Google Scholar
• Laufs U, Custodis F, Bohm M. HMG-CoA reductase inhibitors in chronic heart failure: potential mechanisms of benefit and risk. Drugs 2006;66:145–54
   Google Scholar
• Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248–61
   PubMed Web of Science ®Google Scholar
• Kuller LH. Statins and dementia. Curr Atheroscler Rep 2007;9:154–61
   PubMedGoogle Scholar
• Gonyeau MJ. Statins and osteoporosis: a clinical review. Pharmacotherapy 2005;25:228–43
   PubMed Web of Science ®Google Scholar
• Uzzan B, Cohen R, Nicolas P, et al. Effects of statins on bone mineral density: a meta-analysis of clinical studies. Bone 2007;40:1581–7
   PubMed Web of Science ®Google Scholar